<DOC>
	<DOCNO>NCT02013479</DOCNO>
	<brief_summary>Our aim investigate selenium supplementation versus placebo adjuvant standard treatment levothyroxine ( LT4 ) patient autoimmune thyroiditis lead improve thyroid specific quality life , reduce autoimmune activity . The trial include 472 participant ( 2 X 236 ) four clinical trial site .</brief_summary>
	<brief_title>Selenium Supplementation Autoimmune Thyroiditis</brief_title>
	<detailed_description>Background : Chronic autoimmune thyroiditis ( AIT ) common autoimmune disease often lead impaired function thyroid gland , increase incidence age , 8-9 time female preponderance . Quality life often impaired complaint persist considerable number patient , even restoration euthyroidism . The autoimmune component disease suggest explanation . Selenium micro nutritive essential human health thyroid gland high selenium concentration human tissue . Selenoproteins catalyse thyroid hormone metabolism anti-oxidative process thyrocytes . In addition important immune function . In Denmark , patient AIT low blood selenium concentration background population . The majority 13 randomised trial show selenium supplementation decrease serum thyroid peroxidase antibody level ( TPO-Ab ) patient AIT , compare placebo . We hypothesise adjuvant selenium may beneficial treatment AIT . Objectives : To investigate selenium supplementation versus placebo adjuvant standard treatment levothyroxine ( LT4 ) patient AIT lead improve thyroid specific quality life , reduce autoimmune activity . Design trial size : The CATALYST trial investigator-initiated randomise , blind , multicentre clinical trial selenium supplementation versus placebo patient AIT . The trial include 472 participant ( 2 X 236 ) four clinical trial site . Intervention duration : The experimental intervention group receive 200 μg selenium-enriched yeast two oral tablet daily 12 month . The control group receive two placebo tablet , identical appearance , taste smell , daily 12 month . Six month additional follow-up lead trial duration 18 month . The experimental supplement SelenoPrecise® Pharma Nord ApS . Time schedule : July 2012 - February 2014 : preparation , approval trial registration . March 2014 : first participant first visit . March 2016 : last participant first visit . September 2017 : last participant last visit . Autumn 2017 : analysis biological sample data , preparation manuscript .</detailed_description>
	<mesh_term>Thyroiditis</mesh_term>
	<mesh_term>Thyroiditis , Autoimmune</mesh_term>
	<mesh_term>Hashimoto Disease</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<criteria>1 . Age ≥18 year . 2 . SerumTPOAb ≥ 100 IU/mL measure within last 12 month . 3 . Receiving LT4 treatment . SerumTSH ≥ 4.0 mU/L measure prior treatment initiation 4 . Written informed consent . 1 . Previous diagnosis toxic nodular goitre , Graves ' hyperthyroidism , postpartum thyroiditis thyroid associate orbitopathy ( TAO ) . 2 . Previous radioiodine therapy , antithyroid treatment thyroid surgery . 3 . Previous diagnosis nonmelanoma skin cancer . 4 . Morbidity , render participant unable process patient report outcomes receive intervention trial . 5 . Systemic immunomodulatory medication . 6 . Other medication know affect thyroid function . 7 . Pregnancy , breastfeeding , plan pregnancy within 18 month . 8 . Allergy towards component selenium placebo pill . 9 . Intake selenium supplementation ≥ 55 μg/d . 10 . Unable read understand Danish . 11 . Lack inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>